DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Peter Lawson - 2 Lawson - 2 Scott Schoenhaus - 1 Chris Gibson - 1 Jensen Huang - 1 Leerink - 1 Mani Foroohar - 1 Foroohar - 1
Top related locs:
U.S biopharma Biohive
Top related orgs:
Therapeutics - 2 Barclays - 2 Analysts - 1 Capital - 1 Nvidia - 1 ARK Investment Management - 1 REC - 1 CCM - 1

Search resuls for: "RLY"


3 mentions found


☆ Investors want proof AI will aid drug discovery. Evidence may come in the second half
  + stars: | 2024-07-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +10 min
Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.
Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive
☆ Barclays upgrades a little-known biotech stock that it says can more than double
  + stars: | 2024-05-10 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
Barclays thinks Relay Therapeutics stock can benefit from progress in drug tests to get a proposed breast cancer treatment approved, boosting the stock. Relay stock has slumped 40% in 2024. "We believe the 2H update will help show the superior efficacy/safety profile for Relay's PI3Kalpha (RLY-2608) over existing PI3Kalpha inhibitors like alpelisib and inavolisib," Lawson said. Barclays sees a 70% chance of positive data emerging from an expanded Phase 1 study of RLY-2608 (+fulvestrant) in advanced HR+/HER2- breast cancer. That outcome, "all else equal, could potentially drive the stock up $5 while negative data could drive the stock down $2," the bank said.
Persons: Peter Lawson, Relay's, Lawson Organizations: Barclays, Therapeutics
☆ Pentagon leak suspect Jack Teixeira boasted online he'd thought of everything and was untraceable, FBI investigator says. Now he faces decades in prison.
  + stars: | 2023-04-27 | by ( Grace Eliza Goodwin | Jake Epstein | ) www.businessinsider.com   time to read: +3 min
The Pentagon leak suspect allegedly boasted on social media that he was untraceable and had thought of everything. But FBI investigators found him by asking Discord for the subscriber info connected to his username. Teixeira is suspected of leaking hundreds of classified documents and faces up to 25 years in prison. In new court documents filed late Wednesday evening, an FBI investigator, special agent Luke Church, revealed a number of incriminating text exchanges between Teixeira and other users on the platform. Teixeira was arrested on April 13 and now faces up to 25 years in prison.
0 next >>
Total: 3